Clinical Guidelines and Standards Guidelines by Clinical Area

Testing and interpreting measures of ovarian reserve: a committee opinion

Practice Committee of the American Society for Reproductive Medicine

Committee members: Alan Penzias, Ricardo Azziz, Kristin Bendikson, Tommaso Falcone, Karl Hansen, Micah Hill, William Hurd, Sangita Jindal, Suleena Kalra, Jennifer Mersereau, Catherine Racowsky, Robert Rebar, Richard Reindollar, Chevis N Shannon, Anne Steiner, Dale Stovall, Cigdem Tanrikut, Hugh Taylor, Belinda Yauger

Published December 2020 Fertility and sterility, 114(6), 1151-1157
DOI 10.1016/j.fertnstert.2020.09.134 PMID 33280722

RRM Academy Synopsis

Ovarian reserve tests poorly predict fertility, ASRM committee says

Ovarian reserve tests poorly predict a woman's chance of getting pregnant, the American Society for Reproductive Medicine finds in a 2020 committee opinion. The committee notes the tests can help predict how many eggs stimulation yields. Age, it adds, is a much stronger predictor of reproductive success. The committee says ovarian reserve tests should not be used to judge fertility.

Key Findings

  • The committee cites a trial of 1,202 women aged 18–40 with one or more pregnancy losses. Similar shares of those with low and normal anti-Müllerian hormone (AMH) became pregnant.
  • The committee cites a cohort of 750 women aged 30–44 without known infertility risk. By 6 and 12 cycles of trying, similar shares with low and normal AMH had become pregnant.
  • Based on limited data, the committee finds ovarian reserve tests appear no more useful than age alone for predicting unassisted pregnancy in women with infertility.
  • AMH and antral follicle count are the most sensitive markers, the committee says, but only weakly tied to egg quality, clinical pregnancy and live birth after in vitro fertilization (IVF).
  • The committee advises against using ovarian reserve markers to test fertility in women without known infertility, or to promote planned egg freezing.

Interpretation

The paper is a committee opinion, an expert panel's review of published studies, and it replaces the committee's 2012 version. The committee defines ovarian reserve as the number of eggs left in the ovaries and treats egg quality as a separate trait. The committee ties egg quality to a fertilized egg's chance of becoming a live-born baby. The review weighs cohort studies, trials and pooled analyses. Together they cover women with unproven fertility, women with infertility and women going through IVF.

RRM Context

Restorative reproductive medicine evaluates fertility in the couple. That evaluation draws on charted cycles, ovulation and the male partner's health, so a single egg-count marker is one part of the picture. The committee's review fits that view. The pregnancy model it cites for infertile couples already weighs female age, years of trying, past pregnancy and semen analysis. Ovarian reserve tests appear to add no clinically meaningful gain to that model, the committee finds. A root-cause approach reads a low AMH result as a question about why the reserve is low.

Abstract

Ovarian reserve is defined as the number of oocytes remaining in the ovary, or oocyte quantity (oocyte number). Markers of ovarian reserve include hormone levels and sonographically measured features of the ovaries. These markers can be useful as predictors of oocyte yield following controlled ovarian stimulation and oocyte retrieval. However, they are poor predictors of reproductive potential independently from age. This document replaces the document of the same name last published in 2012 (Fertil Steril 2012;98:1407-15).

Topics

By this author

Related research

Clinical Guidelines and Standards › Guidelines by Clinical Area › Fertility and Infertility Guidelines · Diagnostics › Hormone Testing › Serum Panels · Research Methods › Evidence Synthesis › Systematic Reviews
Alan Penzias, Ricardo Azziz, Kristin Bendikson, Tommaso Falcone, Karl Hansen, Micah Hill, William Hurd, Sangita Jindal, Suleena Kalra, Jennifer Mersereau, Catherine Racowsky, Robert Rebar, Richard Reindollar, Chevis N Shannon, Anne Steiner, Dale Stovall, Cigdem Tanrikut, Hugh Taylor, Belinda Yauger
A Penzias, R Azziz, K Bendikson, T Falcone, K Hansen, M Hill, Bill Hurd, Will Hurd, Billy Hurd, W Hurd, S Jindal, S Kalra, Jen Mersereau, Jenny Mersereau, J Mersereau, Cathy Racowsky, Kate Racowsky, C Racowsky, Bob Rebar, Rob Rebar, Bobby Rebar, R Rebar, Rick Reindollar, Dick Reindollar, Rich Reindollar, R Reindollar, C Shannon, A Steiner, D Stovall, C Tanrikut, H Taylor, B Yauger
PMID 33280722 33280722 DOI 10.1016/j.fertnstert.2020.09.134 10.1016/j.fertnstert.2020.09.134 Practice Committee of the American Society for Reproductive Medicine et al. 2020, Practice Committee of the American Society for Reproductive Medicine 2020